Common Cold News and Research

RSS

New peptide-like molecules could treat herpes, COVID-19, and the common cold

Among the powerful biochemicals of the human immune system, peptides are one of the best.

24 May 2021

Could saffron be an effective supplement for helping manage COVID-19?

A new study, published in the journal Cell Press, explores the potential use of saffron (Crocus sativus L.) as a drug supplement for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19).

24 May 2021

Novel broad-spectrum antiviral compounds effective against Zika and SARS-CoV-2

A research team at the University of Alberta, Canada, led by Dr. Daniel Limonta, has described two novel molecules with broad antiviral properties that are effective against a range of virus types, including SARS-CoV-2.

21 May 2021

Researchers speculate the low prevalence of COVID-19 in Japan

Protective immune memory--through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells--can be induced by identical but also by related viruses.

20 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

Tympanostomy tubes have no long-term benefits for childhood ear infections

There is no long-term benefit to surgically placing tympanostomy tubes in a young child's ears to reduce the rate of recurrent ear infections during the ensuing two years compared with giving oral antibiotics to treat ear infections, a randomized trial led by UPMC Children's Hospital of Pittsburgh and University of Pittsburgh pediatrician-scientists determined.

13 May 2021

Study reports vitamin C inhibits SARS-CoV-2 virus main protease

Based on structural analysis, researchers found that vitamin C binds to 3CLpro, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease essential in viral replication. In vitro cell inhibition studies also showed vitamin C could inhibit 3CLpro, indicating a possible new antiviral treatment method.

6 May 2021

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

5 May 2021

Arresting tumor growth for a variety of cancers through T cell engineering

Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues.

30 Apr 2021

Delayed antibiotic prescribing unlikely to lead to poorer symptom control

Delayed antibiotic prescribing is a safe and effective strategy for most patients with respiratory tract infections, finds an analysis of patient data published by The BMJ today.

30 Apr 2021

Virtual care spreads in Missouri health system, home to ‘hospital without beds’

When Tom Becker was diagnosed with an irregular heartbeat in March 2020, the 60-year-old EMS helicopter pilot from Washington, Missouri, worried he would never fly again.

23 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Researchers explain how online symptom checkers generate probable diagnoses and suggestions

Have you recently turned to your mobile device or computer to find out if your cough, sniffle or fever could be caused by COVID-19?

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Researchers at The Scripps Research Institute, USA, have described a potential target for COVID-19 vaccines. Dubbed as CC40.8 bnAb, it exhibited broad reactivity with human beta coronaviruses.

1 Apr 2021

Study: COVID-19 vaccines may remain effective against new influenza viruses

Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses.

26 Mar 2021

FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

25 Mar 2021

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

24 Mar 2021